Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
47.96
-0.75 (-1.54%)
Dec 26, 2025, 4:00 PM EST - Market closed
Crinetics Pharmaceuticals Employees
Crinetics Pharmaceuticals had 437 employees as of December 31, 2024. The number of employees increased by 147 or 50.69% compared to the previous year.
Employees
437
Change (1Y)
147
Growth (1Y)
50.69%
Revenue / Employee
$3,513
Profits / Employee
-$968,185
Market Cap
4.55B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 437 | 147 | 50.69% |
| Dec 31, 2023 | 290 | 80 | 38.10% |
| Dec 31, 2022 | 210 | 67 | 46.85% |
| Dec 31, 2021 | 143 | 50 | 53.76% |
| Dec 31, 2020 | 93 | 25 | 36.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRNX News
- 8 days ago - Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 15 days ago - Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) - GlobeNewsWire
- 16 days ago - Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors - GlobeNewsWire
- 5 weeks ago - Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome - GlobeNewsWire
- 6 weeks ago - Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire